We are thrilled to highlight these 16 SGO abstract acceptances and other recent highlights from members of the Gynecologic Oncology division. #SGOMtg

SGO meeting website »

SGO schedule »

2022 SGO committee appointments 

Wellness committee –Toboni, Hagemann  

Clinical Practice Committee – McCourt (ACOG Liaison) 

Publications Committee – Mullen 

Annual Meeting Program and Steering Committee – Hagemann 

Diversity, Inclusion and Health Equity Committee – Kuroki 

Poster Presentations

Developments in Translational Science and Cancer Biology  

  1. Bruce S, Cho K, Noia H, Lomonosova E, Stock E, Oplt A, Blachut B, Kuroki L, Mullen M, Hagemann A, McCourt C, Thaker P, Khabele D, Powell M, Shriver L, Patti G, Fuh K. GAS6-AXL inhibition by AVB-500 overcomes resistance to paclitaxel in endometrial cancer by decreasing tumor cell glycolysis.  
    Accepted: Poster  
  1. Cohen A, Kuo I, Nigaglioni A, Fuh K, Hagemann A, Khabele D, Kuroki L, Mullen M, Mutch D, Powell M, Thaker P, Huang Y, Markovina S. Overall survival with or without adjuvant radiotherapy among different molecular subtypes of endometrial cancer.  
    Accepted: Poster  
  1. Cohen A, Nigaglioni A, Kuo I, Fuh K, Hagemann A, Khabele D, Kuroki L, Mullen M, Mutch D, Powell M, Thaker P, Huang Y, Markovina S. Combining molecular subtype and traditional histo-pathologic classifications tumor to predict survival in patients with endometrioid or serous endometrial cancers  
    Accepted: Poster  
  1. Tankou J, Oplt A, Toboni M, Bruce S, Noia H, Wilke D, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Fuh K. AVB-S6-500, a receptor tyrosine kinase AXL inhibitor, improves the therapeutic efficacy of Trastuzumab in uterine serous cancers  
    Accepted: Poster  
  1. Stock E, Lomonosova E, Noia H, Bruce S, Grither W, Mullen M, Khabele D, Kuroki L, Hagemann A, McCourt C, Thaker P, Mutch D, Powell M, Patti G, Longmore G, Fuh K. Pharmacologic inhibition of Discoidin Domain Receptor 2 (DDR2) sensitizes homologous recombination proficient ovarian cancer models to treatment with olaparib.  
    Accepted: Poster  
  1. Valentine M, Bruce S, Kotnik E, Hagemann I, Hagemann A, Kuroki L, McCourt C, Khabele D, Powell M, Thaker P, Mutch D, Fuh K. Characterization of the mutational landscape of high-grade serous ovarian tumors before and after neo-adjuvant chemotherapy  
    Accepted: Poster  
  1. Grither W, Morikis V, Baker B, Hagemann A, Khabele D, Kuroki L, McCourt C, Mutch D, Powell M, Thaker P, Fuh K, Longmore G. ROR2-Vangl2 complexes direct ovarian cancer cell motility in response to Wnt5a 
    Accepted: Poster   
  1. Grither W, Baker B, Hagemann A, Khabele D, Kuroki L, McCourt C, Mutch D, Powell M, Thaker P, Fuh K, Longmore G. ROR2 can function independent of tyrosine kinase activity to promote ovarian cancer metastasis 
    Accepted: Poster  

Disparities/inequalities in cancer care  

  1. Wilson E, Stock E, Huang R, Buchanan T, Kotnik E, Mullen M, Khabele D, Kuroki L, Fuh K, McCourt C, Thaker P, Massad LS, Mutch D, Powell M, Hagemann A. Germline and somatic genetic testing trends among women with epithelial ovarian cancer  
    Accepted: Poster  
  2. Wilson E, Stock E, Huang R, Buchanan T, Kotnik E, Mullen M, Khabele D, Kuroki L, Fuh K, McCourt C, Thaker P, Massad LS, Mutch D, Powell M, Hagemann A. Comparison of three testing strategies for germline genetic testing for homologous recombination deficient mutations in women with epithelial ovarian cancer  
    Accepted: Poster  
  3. Blachut B, Vander J, Tippey A, Mazul A, Liebendorfer A, Qureshi R, Hagemann A, Thaker P, Fuh K, McCourt C, Massad LS, Mutch D, Powell M, Khabele D, Kuroki L. Socioeconomic disparities in distress and coping in gynecologic oncology patients.  
    Accepted: Poster  
  4. Bruce S, Huysman B, Bharucha J, Massad LS, Mullen M, Hagemann A, Fuh K, McCourt C, Thaker P, Khabele D, Powell M, Mutch D, Kuroki L. Persistent inequities in access to and continuity of gynecologic oncology care during the COVID-19 pandemic  
    Accepted: Focused plenary oral presentation   

Novel Clinical Programs  

  1. Kosmacki A, Morris D, Vanderlan J, Gallen L, Fuh K, Khabele D, Kuroki L, Massad LS, McCourt C, Mullen M, Mutch D, Powell M, Thaker P, Hagemann A. Cognitive Behavioral Therapy for Weight Management in Gynecologic Oncology.  
    Accepted: Poster  
  2. Wilson E, Bruce S, DeWitt L, Mullen M, Kuroki L, Hagemann A, Fuh K, Thaker P, Khabele D, Powell M, Mutch D, McCourt C. Reducing paclitaxel hypersensitivity reactions in gynecologic oncology patients.  
    Accepted: Poster  
  3. Stock E, Hagemann A. A qualitative analysis of patient- and provider-perceived barriers and facilitators to cascade genetic testing for hereditary breast, ovarian, endometrial and colorectal cancer.  
    Accepted: Poster  

Breakthroughs in Precision Medicine/Rare Tumor Studies  

  1. Bruce S, Blachut B, Tunnage I, Mintz R, Liebendorfer A, Joshi T, Cummings M, Stasenko M, Shahin M, Hagemann I, Mullen M, Kuroki L, Hagemann A, McCourt C, Thaker P, Khabele D, Mutch D, Powell M. Effect of sentinel lymph node isolated tumor cells on recurrence free survival in patients with mismatch repair proficient vs. deficient stage I/II endometrioid endometrial adenocarcinoma  
    Accepted: Poster